Sunday, Jul 05

Hydroxychloroquine trials for coronavirus to resume

Trump said in March hydroxychloroquine could be a game-changer and then said he was taking it himself.
30.06.2020 - 18:00

A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with coronavirus is to restart after being approved by British regulators.

THE STUDY WAS PAUSED

The Medicines and Healthcare Products Regulatory Agency (MHRA) took its decision on what is known as the COPCOV trial after hydroxychloroquine was found in another British trial to have no benefit as a treatment for patients already infected with coronavirus, the disease caused by the new coronavirus.

The COPCOV study was paused pending review after the treatment trial results.

It is a randomised, placebo-controlled trial that is aiming to enrol 40,000 healthcare workers and other at-risk staff around the world, and is being led by the Oxford University’s Mahidol Oxford Tropical Medicine Research Unit (MORU) in the Thai capital, Bangkok.